Researchers are exploring the use of nanomedicines that respond to the tumor microenvironment to enhance cancer immunotherapy. These nanomedicines are being designed to target various aspects of the tumor environment, including glucose transporters and immunosuppressive mechanisms, in different types of cancer, such as colorectal, lung, and breast cancer. The goal of these approaches is to create more effective cancer treatments by potentiating immunotherapy and reprogramming the tumor microenvironment.